<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02081534</url>
  </required_header>
  <id_info>
    <org_study_id>D5613C00001</org_study_id>
    <nct_id>NCT02081534</nct_id>
  </id_info>
  <brief_title>Dose Finding Study to Treat High Phosphate Levels in the Blood.</brief_title>
  <official_title>A Phase 2b, Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicentre Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of AZD1722 to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardelyx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardelyx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized. double blind, placebo controlled, parallel arms dose finding study with a 4 weeks&#xD;
      treatment period&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a screening period of approximately 1 week, a wash out period of up to&#xD;
      3 weeks, where existing phosphate lowering medication is withheld, a 4-week treatment period&#xD;
      and a follow-up period of up to 2 weeks, during which patients are put back on their pre&#xD;
      washout phosphate lowering medication.&#xD;
&#xD;
      The wash out period will be either 1 week, 2 weeks or 3 weeks depending on the increase in&#xD;
      s-phosphate levels.&#xD;
&#xD;
      There are 7 parallel treatment arms in the study with bid and od treatment regimens.&#xD;
&#xD;
      Laboratory efficacy endpoints and safety assessments will be evaluated at various times&#xD;
      throughout the study.&#xD;
&#xD;
      The target population of the study is: male or female patients, above18 years of age with End&#xD;
      Stage Renal Disease (ESRD) on chronic maintenance hemodialysis (HD) 3 times a week for a&#xD;
      minimum of 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum Phosphate Levels</measure>
    <time_frame>End of wash out (pre randomization value) to end of treatment (Day 29)</time_frame>
    <description>Change in serum phosphate levels from the end of wash out (pre randomization value) to end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Calcium x Phosphorus Product</measure>
    <time_frame>End of wash out (pre randomization value) to end of treatment (Day 29)</time_frame>
    <description>Change from baseline (end of wash out) in calcium x phosphorus product</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>1 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg AZD1722 bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg AZD1722 bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg AZD1722 bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg AZD1722 bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg od</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg AZD1722 od</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg od</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg AZD1722 od</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (double dummy technique)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1722</intervention_name>
    <description>AZD1722, oral tablet</description>
    <arm_group_label>1 mg bid</arm_group_label>
    <arm_group_label>10 mg bid</arm_group_label>
    <arm_group_label>3 mg bid</arm_group_label>
    <arm_group_label>3 mg od</arm_group_label>
    <arm_group_label>30 mg bid</arm_group_label>
    <arm_group_label>30 mg od</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo bid, double dummy technique</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females and males aged â‰¥18 years&#xD;
&#xD;
          2. Chronic maintenance hemodialysis 3 x/week for a at least 3 months&#xD;
&#xD;
          3. Prescribed and taking at least 3 doses of phosphate binder per day&#xD;
&#xD;
          4. Serum phosphate levels should be between 3.5 and 8.0 mg/dL ; 1.13 mmol/L and 2.58&#xD;
             mmol/L (inclusive) at screening&#xD;
&#xD;
          5. Total serum calcium levels 2.0 - 2.6 mmol/L inclusive at screening&#xD;
&#xD;
          6. For randomization in the study, after up to 3 weeks wash out of phosphate binders,&#xD;
             patients must have serum phosphate levels of at least 6. 0 mg/dL (1.94 mmol/L) but&#xD;
             below 10 mg/dL (3.23 mmol/L) and have had an increase of at least 1.5 mg/dL (0.48&#xD;
             mmol/L) vs pre wash out&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe hyperphosphatemia defined as &gt;10 mg/dL on Phosphate-binders at all time points&#xD;
             during clinical routine monitoring for the 3 preceding months before screening visit.&#xD;
&#xD;
          2. Serum parathyroid hormone &gt;1200 pg/mL&#xD;
&#xD;
          3. Significant metabolic acidosis&#xD;
&#xD;
          4. Clinical signs of hypovolemia at randomization&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey A Block, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver Nephrology PC, Denver, CO 80230</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maspeth</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Czestochowa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dzialdowo</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Legnica</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Radom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zamosc</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zary</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zgierz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hlohovec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piestany</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Puchov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Senica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Doncaster</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 6, 2014</study_first_submitted>
  <study_first_submitted_qc>March 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2014</study_first_posted>
  <results_first_submitted>August 6, 2020</results_first_submitted>
  <results_first_submitted_qc>August 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2020</results_first_posted>
  <last_update_submitted>August 25, 2020</last_update_submitted>
  <last_update_submitted_qc>August 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>S-phosphate, hyperphosphatemia, hemodialysis, ESRD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1 mg Bid</title>
          <description>1 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="P2">
          <title>3 mg Bid</title>
          <description>3 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="P3">
          <title>10 mg Bid</title>
          <description>10 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="P4">
          <title>30 mg Bid</title>
          <description>30 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="P5">
          <title>3 mg od</title>
          <description>3 mg AZD1722 od&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="P6">
          <title>30 mg od</title>
          <description>30 mg AZD1722 od&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="P7">
          <title>Placebo</title>
          <description>Placebo (double dummy technique)&#xD;
Placebo: Placebo bid, double dummy technique</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="22"/>
                <participants group_id="P6" count="21"/>
                <participants group_id="P7" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 mg Bid</title>
          <description>1 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="B2">
          <title>3 mg Bid</title>
          <description>3 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="B3">
          <title>10 mg Bid</title>
          <description>10 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="B4">
          <title>30 mg Bid</title>
          <description>30 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="B5">
          <title>3 mg od</title>
          <description>3 mg AZD1722 od&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="B6">
          <title>30 mg od</title>
          <description>30 mg AZD1722 od&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="B7">
          <title>Placebo</title>
          <description>Placebo (double dummy technique)&#xD;
Placebo: Placebo bid, double dummy technique</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="22"/>
            <count group_id="B6" value="21"/>
            <count group_id="B7" value="26"/>
            <count group_id="B8" value="162"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" spread="14.79"/>
                    <measurement group_id="B2" value="61.5" spread="11.21"/>
                    <measurement group_id="B3" value="62.7" spread="12.53"/>
                    <measurement group_id="B4" value="59.7" spread="12.96"/>
                    <measurement group_id="B5" value="57.6" spread="15.78"/>
                    <measurement group_id="B6" value="58.2" spread="15.75"/>
                    <measurement group_id="B7" value="56.1" spread="13.14"/>
                    <measurement group_id="B8" value="59.1" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="17"/>
                    <measurement group_id="B8" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>serum phosphorus</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.55" spread="1.003"/>
                    <measurement group_id="B2" value="7.92" spread="1.005"/>
                    <measurement group_id="B3" value="7.32" spread="1.063"/>
                    <measurement group_id="B4" value="7.76" spread="1.183"/>
                    <measurement group_id="B5" value="7.73" spread="1.276"/>
                    <measurement group_id="B6" value="7.61" spread="0.847"/>
                    <measurement group_id="B7" value="7.87" spread="1.488"/>
                    <measurement group_id="B8" value="7.68" spread="1.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Phosphate Levels</title>
        <description>Change in serum phosphate levels from the end of wash out (pre randomization value) to end of treatment</description>
        <time_frame>End of wash out (pre randomization value) to end of treatment (Day 29)</time_frame>
        <population>two patients in the 30 mg bid group are not included in the analysis since they had no post randomization serum phosphorus measurements</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg Bid</title>
            <description>1 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>3 mg Bid</title>
            <description>3 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
          </group>
          <group group_id="O3">
            <title>10 mg Bid</title>
            <description>10 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
          </group>
          <group group_id="O4">
            <title>30 mg Bid</title>
            <description>30 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
          </group>
          <group group_id="O5">
            <title>3 mg od</title>
            <description>3 mg AZD1722 od&#xD;
AZD1722: tenapanor, oral tablet</description>
          </group>
          <group group_id="O6">
            <title>30 mg od</title>
            <description>30 mg AZD1722 od&#xD;
AZD1722: tenapanor, oral tablet</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Placebo (double dummy technique)&#xD;
Placebo: Placebo bid, double dummy technique</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Phosphate Levels</title>
          <description>Change in serum phosphate levels from the end of wash out (pre randomization value) to end of treatment</description>
          <population>two patients in the 30 mg bid group are not included in the analysis since they had no post randomization serum phosphorus measurements</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.47" spread="1.553"/>
                    <measurement group_id="O2" value="-1.18" spread="1.391"/>
                    <measurement group_id="O3" value="-1.7" spread="2.018"/>
                    <measurement group_id="O4" value="-1.98" spread="2.007"/>
                    <measurement group_id="O5" value="-.56" spread="1.763"/>
                    <measurement group_id="O6" value="-1.11" spread="1.469"/>
                    <measurement group_id="O7" value="-.54" spread="1.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Calcium x Phosphorus Product</title>
        <description>Change from baseline (end of wash out) in calcium x phosphorus product</description>
        <time_frame>End of wash out (pre randomization value) to end of treatment (Day 29)</time_frame>
        <population>The number of patients analyzed are less than the randomized number since the data to accomplish the analysis was not available.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg Bid</title>
            <description>1 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>3 mg Bid</title>
            <description>3 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
          </group>
          <group group_id="O3">
            <title>10 mg Bid</title>
            <description>10 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
          </group>
          <group group_id="O4">
            <title>30 mg Bid</title>
            <description>30 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
          </group>
          <group group_id="O5">
            <title>3 mg od</title>
            <description>3 mg AZD1722 od&#xD;
AZD1722: tenapanor, oral tablet</description>
          </group>
          <group group_id="O6">
            <title>30 mg od</title>
            <description>30 mg AZD1722 od&#xD;
AZD1722: tenapanor, oral tablet</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Placebo (double dummy technique)&#xD;
Placebo: Placebo bid, double dummy technique</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Calcium x Phosphorus Product</title>
          <description>Change from baseline (end of wash out) in calcium x phosphorus product</description>
          <population>The number of patients analyzed are less than the randomized number since the data to accomplish the analysis was not available.</population>
          <units>mg/dL * mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.16" spread="9.75"/>
                    <measurement group_id="O2" value="-12.02" spread="14.02"/>
                    <measurement group_id="O3" value="-12.44" spread="15.94"/>
                    <measurement group_id="O4" value="-16.6" spread="18.01"/>
                    <measurement group_id="O5" value="-3.59" spread="18.59"/>
                    <measurement group_id="O6" value="-11.02" spread="11.57"/>
                    <measurement group_id="O7" value="-2.50" spread="13.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for a total of 5 weeks; 4-weeks of treatment and 1 treatment-free week</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1 mg Bid</title>
          <description>1 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="E2">
          <title>3 mg Bid</title>
          <description>3 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="E3">
          <title>10 mg Bid</title>
          <description>10 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="E4">
          <title>30 mg Bid</title>
          <description>30 mg AZD1722 bid&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="E5">
          <title>3 mg od</title>
          <description>3 mg AZD1722 od&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="E6">
          <title>30 mg od</title>
          <description>30 mg AZD1722 od&#xD;
AZD1722: tenapanor, oral tablet</description>
        </group>
        <group group_id="E7">
          <title>Placebo</title>
          <description>Placebo (double dummy technique)&#xD;
Placebo: Placebo bid, double dummy technique</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="26"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E6" events="11" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Development Officer</name_or_title>
      <organization>Ardelyx</organization>
      <phone>6175134929</phone>
      <email>drosenbaum@ardelyx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

